Evidence map›Paper›PMID 40467942›Full record

ReviewMedical oncology (Northwood, London, England)2025

Advancing the potential of nanoparticles for cancer detection and precision therapeutics.

Muhammad Naeem Kiani, Hamza Khaliq, Muhammad Abubakar, Merium Rafique, Fazliddin Jalilov, Ghulam Abbas Ashraf, Amel Ayari-Akkari, Ali Akremi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Muhammad Naeem KianiGuangdong Key Laboratory of Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, China. naeemkiani777@gmail.com.
Hamza KhaliqCollege of Environment, Hohai University, Nanjing, 210098, China.
Muhammad AbubakarAcademy of Medical Engineering and Translational Medicine, Medical College, Tianjin University, Tianjin, China.
Merium RafiqueDepartment of Chemistry, University of Azad, Jammu and Kashmir, Pakistan.
Fazliddin JalilovAlfraganus University, Yukori Karakamish Street 2a, 100190, Tashkent, Uzbekistan.
Ghulam Abbas AshrafCollege of Environment, Hohai University, Nanjing, 210098, China.
Amel Ayari-AkkariBiology Department, College of Science, King Khalid University, P.O. Box 960, Abha, Saudi Arabia.
Ali AkremiDepartment of Chemistry, Faculty of Science, Northern Border University, Arar, Saudi Arabia.

Funding

Deanship of Research and Graduate Studies at King Khalid University, (RGP.2/286/45)Deanship of Scientific Research at Northern Border University, Arar, KSA NBU-FFR-2025-2246-10.
6 · The paper itself

Abstract

Cancer poses a significant challenge with high death rate marked by heterogeneity, complexity, and resistance to available treatments, hence requiring creative approaches to improve early detection and precision medicines. Nanoparticles (NPs) exhibit distinctive physicochemical characteristics, including a high surface area-to-volume ratio, adjustable size and shape, and multifunctionality. This review paper critically explored the recent advancements in various NPs, such as graphene-based materials (to overcome cancer resistance and for diagnostic and therapeutics applications), metal organic frameworks (precised and targeted release of drug, e.g., glutathione-sensitive disulfide bonds for intracellular delivery), carbon dots, rhodamine 6G, polymer-based nanoformulation (CAP/ZnO NPs for lung cancer therapy), gold NPs (as radiosensitizing action), nanocarrier systems (including epigenetic control systems), aptamers, mesoporous polydopamine-based nanodrug, polymeric NPs, pH-responsive polymeric nanostructures (particularly in acidic tumor environment), multifunctional NPs, and carbon coated ferrite nanodots for targeted delivery to cancer cells. We, particularly, investigated their dual abilities in precise drug delivery of several payloads, like small molecules, proteins, and nucleic acids, in addition to their capabilities for real-time monitoring of therapeutic response in malignant cells. Moreover, this review underscores how the integration of Artificial Intelligence and machine learning algorithms with such NPs-based architectures is improving diagnostic precision and facilitating personalized cancer therapy approaches, navigating obstacles, including bioavailability and multidrug resistance. By evaluating critical recent breakthroughs about the role of nanotechnology in precision cancer therapy, this review paper highlights the pioneering capabilities of such intelligent nanomedicines in impacting cancer development, consequently advancing patient outcomes.

Indexed as

NanoparticlesNeoplasmsPrecision MedicineAnimalsDrug Delivery SystemsHumansAI/MLCancer theranosticsDiagnosisNanomedicinesNanotechnologyPersonalized treatmentTumor microenvironment

Identifiers

PMID40467942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.